Episurf Medical AB (publ) held an extraordinary general meeting in Stockholm today, on 13 April 2026.

Approval of two amendments to the articles of association and authorisation in relation to the Frusipe Acquisition

The extraordinary general meeting resolved, in accordance with the board of directors' proposal, on two amendments to the articles of association, regarding the limits for the share capital and the number of shares, in order to enable issues that the board of directors intends to resolve upon pursuant to an authorisation in order to complete the acquisition of Frusipe Intressenter Target 1 AB from Frusipe Intressenter Holding AB (the "Frusipe Acquisition"). The Frusipe Acquisition is described in further detail in the press release announced by the company on 30 December 2025.

The extraordinary general meeting also resolved, in accordance with the board of directors' proposal, to authorise the board of directors, during the period until the next annual general meeting, on one or more occasions, to resolve on issues of Class B shares, convertibles convertible into Class B shares, and warrants entitling to subscription of Class B shares. The authorisation may only be utilised to complete the Frusipe Acquisition and to fulfil the company's obligations under the Frusipe Acquisition.

Approval of acquisition, amendment to the articles of association, and authorisation in relation to the KlaraBo Acquisition

The extraordinary general meeting resolved, in accordance with the board of directors' proposal, to approve the acquisition of KlaraBo Empire Holding AB from KlaraBo Empire Top Holding AB (the "KlaraBo Acquisition"). The KlaraBo Acquisition is described in further detail in the press release announced by the company on 26 January 2026.

The extraordinary general meeting also resolved, in accordance with the board of directors' proposal, to approve an amendment to the articles of association, regarding the limits for share capital and the number of shares, in order to enable the share issue that the board of directors intends to resolve upon pursuant to an authorisation, to complete the KlaraBo Acquisition.

The extraordinary general meeting also resolved, in accordance with the board of directors' proposal, to authorise the board of directors, during the period until the next annual general meeting, on one or more occasions, to resolve on an issue of Class B shares. The authorisation may only be utilised to complete the KlaraBo Acquisition and to fulfil the company's obligations under the KlaraBo Acquisition.

Election of member of the board of directors etc.

The extraordinary general meeting also resolved that the number of ordinary board members elected by a general meeting shall be four, that Lars Lönnquist is elected as a member of the board of directors for the period until the end of the next annual general meeting, and that an annual remuneration of SEK 200,000 shall be paid to Lars Lönnquist, whereby the remuneration paid shall be calculated on a pro rata basis from and including the date of the extraordinary general meeting held on 13 April 2026, up to and including the date of the next annual general meeting. The extraordinary general meeting further resolved that a corresponding pro rata calculation shall be applied to the remuneration of members of the board of directors who have resigned from and including the date of the annual general meeting held on 10 April 2025, up to and including the date of their respective resignation.

For additional information about the proposals approved by the extraordinary general meeting, please refer to the notice to the extraordinary general meeting, published on 11 March 2026.

For further details, please contact:

Jens Andersson, CEO, Episurf Medical

Tel: +46 (0) 768 55 67 02

Email: [email protected]

About Episurf Medical

Episurf Medical is a real estate company with exposure to a diversified portfolio of real estate assets. The Company's objective is to create value growth through the acquisition and management of Nordic properties. The Company also has a medical technology business based on the patient-specific implant Episealer® and associated surgical instruments, used to treat cartilage damage in joints. Episurf Medical's head office is located in Stockholm, Sweden.